144 related articles for article (PubMed ID: 26825641)
1. The Complexities of Interpreting Reversible Elevated Serum Creatinine Levels in Drug Development: Does a Correlation with Inhibition of Renal Transporters Exist?
Chu X; Bleasby K; Chan GH; Nunes I; Evers R
Drug Metab Dispos; 2016 Sep; 44(9):1498-509. PubMed ID: 26825641
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Renal Transporter Inhibition Using Creatinine as a Substrate In Vitro to Assess the Clinical Risk of Elevated Serum Creatinine.
Mathialagan S; Rodrigues AD; Feng B
J Pharm Sci; 2017 Sep; 106(9):2535-2541. PubMed ID: 28416419
[TBL] [Abstract][Full Text] [Related]
3. Prediction of clinical drug-drug interactions of veliparib (ABT-888) with human renal transporters (OAT1, OAT3, OCT2, MATE1, and MATE2K).
Kikuchi R; Lao Y; Bow DA; Chiou WJ; Andracki ME; Carr RA; Voorman RL; De Morais SM
J Pharm Sci; 2013 Dec; 102(12):4426-32. PubMed ID: 24122511
[TBL] [Abstract][Full Text] [Related]
4. Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat.
Lepist EI; Zhang X; Hao J; Huang J; Kosaka A; Birkus G; Murray BP; Bannister R; Cihlar T; Huang Y; Ray AS
Kidney Int; 2014 Aug; 86(2):350-7. PubMed ID: 24646860
[TBL] [Abstract][Full Text] [Related]
5. Quantitative Consideration of Clinical Increases in Serum Creatinine Caused by Renal Transporter Inhibition.
Nakada T; Kudo T; Ito K
Drug Metab Dispos; 2023 Sep; 51(9):1114-1126. PubMed ID: 36859345
[TBL] [Abstract][Full Text] [Related]
6. Tucatinib Inhibits Renal Transporters OCT2 and MATE Without Impacting Renal Function in Healthy Subjects.
Topletz-Erickson AR; Lee AJ; Mayor JG; Rustia EL; Abdulrasool LI; Wise AL; Dailey B; DeChenne S; Walker LN; Alley SC; Endres CJ
J Clin Pharmacol; 2021 Apr; 61(4):461-471. PubMed ID: 32989831
[TBL] [Abstract][Full Text] [Related]
7. Fampridine is a Substrate and Inhibitor of Human OCT2, but not of Human MATE1, or MATE2K.
Xiao G; Rowbottom C; Boiselle C; Gan LS
Pharm Res; 2018 Jun; 35(8):159. PubMed ID: 29915999
[TBL] [Abstract][Full Text] [Related]
8. Impact on creatinine renal clearance by the interplay of multiple renal transporters: a case study with INCB039110.
Zhang Y; Warren MS; Zhang X; Diamond S; Williams B; Punwani N; Huang J; Huang Y; Yeleswaram S
Drug Metab Dispos; 2015 Apr; 43(4):485-9. PubMed ID: 25605813
[TBL] [Abstract][Full Text] [Related]
9. Characterization of Organic Anion Transporter 2 (SLC22A7): A Highly Efficient Transporter for Creatinine and Species-Dependent Renal Tubular Expression.
Shen H; Liu T; Morse BL; Zhao Y; Zhang Y; Qiu X; Chen C; Lewin AC; Wang XT; Liu G; Christopher LJ; Marathe P; Lai Y
Drug Metab Dispos; 2015 Jul; 43(7):984-93. PubMed ID: 25904762
[TBL] [Abstract][Full Text] [Related]
10. Significance of Organic Anion Transporter 2 and Organic Cation Transporter 2 in Creatinine Clearance: Mechanistic Evaluation Using Freshly Prepared Human Primary Renal Proximal Tubule Cells.
Mathialagan S; Chung G; Pye K; Rodrigues AD; Varma MVS; Brown C
J Pharmacol Exp Ther; 2024 Jan; 388(1):201-208. PubMed ID: 37977812
[TBL] [Abstract][Full Text] [Related]
11. Estimation of changes in serum creatinine and creatinine clearance caused by renal transporter inhibition in healthy subjects.
Nakada T; Kudo T; Kume T; Kusuhara H; Ito K
Drug Metab Pharmacokinet; 2019 Aug; 34(4):233-238. PubMed ID: 31176593
[TBL] [Abstract][Full Text] [Related]
12. No Inhibition of MATE1/2K-Mediated Renal Creatinine Secretion Predicted With Ritonavir or Cobicistat.
Kikuchi R; Chiou WJ; Kasai MA; de Morais SM; Bow DAJ
J Pharm Sci; 2019 Sep; 108(9):3118-3123. PubMed ID: 31034908
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory Effect of Crizotinib on Creatinine Uptake by Renal Secretory Transporter OCT2.
Arakawa H; Omote S; Tamai I
J Pharm Sci; 2017 Sep; 106(9):2899-2903. PubMed ID: 28336299
[TBL] [Abstract][Full Text] [Related]
14. Quantitative analysis of elevation of serum creatinine via renal transporter inhibition by trimethoprim in healthy subjects using physiologically-based pharmacokinetic model.
Nakada T; Kudo T; Kume T; Kusuhara H; Ito K
Drug Metab Pharmacokinet; 2018 Feb; 33(1):103-110. PubMed ID: 29361388
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of OCT2, MATE1 and MATE2-K as a possible mechanism of drug interaction between pazopanib and cisplatin.
Sauzay C; White-Koning M; Hennebelle I; Deluche T; Delmas C; Imbs DC; Chatelut E; Thomas F
Pharmacol Res; 2016 Aug; 110():89-95. PubMed ID: 27178732
[TBL] [Abstract][Full Text] [Related]
16. Renal uptake of substrates for organic anion transporters Oat1 and Oat3 and organic cation transporters Oct1 and Oct2 is altered in rats with adenine-induced chronic renal failure.
Komazawa H; Yamaguchi H; Hidaka K; Ogura J; Kobayashi M; Iseki K
J Pharm Sci; 2013 Mar; 102(3):1086-94. PubMed ID: 23280877
[TBL] [Abstract][Full Text] [Related]
17. Effect of tyrosine kinase inhibitors on renal handling of creatinine by MATE1.
Omote S; Matsuoka N; Arakawa H; Nakanishi T; Tamai I
Sci Rep; 2018 Jun; 8(1):9237. PubMed ID: 29915248
[TBL] [Abstract][Full Text] [Related]
18. Transporters affecting biochemical test results: Creatinine-drug interactions.
Chu X; Bleasby K; Chan GH; Nunes I; Evers R
Clin Pharmacol Ther; 2016 Nov; 100(5):437-440. PubMed ID: 27509262
[TBL] [Abstract][Full Text] [Related]
19. Mechanistic Models as Framework for Understanding Biomarker Disposition: Prediction of Creatinine-Drug Interactions.
Scotcher D; Arya V; Yang X; Zhao P; Zhang L; Huang SM; Rostami-Hodjegan A; Galetin A
CPT Pharmacometrics Syst Pharmacol; 2020 May; 9(5):282-293. PubMed ID: 32410382
[TBL] [Abstract][Full Text] [Related]
20. Renal tubular transporter-mediated interactions of HIV drugs: implications for patient management.
Gutiérrez F; Fulladosa X; Barril G; Domingo P
AIDS Rev; 2014; 16(4):199-212. PubMed ID: 25350530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
